miRagen Reports Fourth Quarter and Full Year 2019 Financial Results
March 11, 2020 16:05 ET
|
miRagen Therapeutics, Inc.
Completed enrollment of 37 patients in the Phase 2 SOLAR trial of cobomarsen in CTCL; expects to report topline data in Q3 2020Completed initial planned enrollment of the Phase 1 trial of cobomarsen...
miRagen Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on March 11, 2020
February 20, 2020 08:00 ET
|
miRagen Therapeutics, Inc.
BOULDER, Colo., Feb. 20, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
miRagen Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants to Purchase Common Stock
February 07, 2020 09:00 ET
|
miRagen Therapeutics, Inc.
BOULDER, Colo., Feb. 07, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
miRagen Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
February 06, 2020 16:03 ET
|
miRagen Therapeutics, Inc.
BOULDER, Colo., Feb. 06, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
miRagen Therapeutics Announces Positive Data for Cobomarsen in Adult T-Cell Leukemia/lymphoma Patients With Residual Disease
January 30, 2020 07:00 ET
|
Miragen Therapeutics, Inc.
Cobomarsen-treated adult T-cell leukemia/lymphoma (ATLL) patients with residual disease had a median survival time (MST) of 26 months compared with 7.4 months in a historical cohort- - - Median...
miRagen Therapeutics to Present New Cobomarsen Clinical Trial Data for Adult T-Cell Leukemia/Lymphoma at Two Upcoming Conferences
January 23, 2020 08:00 ET
|
Miragen Therapeutics, Inc.
BOULDER, Colo., Jan. 23, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific...
miRagen Announces Major Changes to Company’s Strategy
December 11, 2019 16:05 ET
|
Miragen Therapeutics, Inc.
Expecting topline data in Q3 2020 from truncated Phase 2 SOLAR clinical trial of cobomarsen in CTCL Pursuing guidance from FDA on a clinical development plan for cobomarsen in ATLL; anticipate meeting...
miRagen to Present at the Evercore ISI HealthCONx Conference 2019
November 26, 2019 08:00 ET
|
Miragen Therapeutics, Inc.
BOULDER, Colo., Nov. 26, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific...
miRagen Reports Third Quarter 2019 Results and Provides Corporate Update
November 07, 2019 16:01 ET
|
Miragen Therapeutics, Inc.
Announced positive data from two Phase 1 clinical trials of MRG-110Remain on track to announce interim top-line data from its Phase 2 clinical trial of remlarsen in keloids by year endImplemented...
miRagen to Present at the DIA/FDA Oligonucleotide-Based Therapeutics Conference Today
October 28, 2019 09:00 ET
|
Miragen Therapeutics, Inc.
An overview of its second-generation miR-29 mimicsClinical development of its microRNA inhibitors BOULDER, Colo., Oct. 28, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a...